Update on UT Health RGV COVID-19 vaccine efforts

Translate to Spanish or other 102 languages!

Image for illustration purposes only

Mega Doctor News

- Advertisement -

By UTRGV News & Internal Communications

RIO GRANDE VALLEY, TEXAS – Based on guidance recently obtained from State of Texas officials, UT Health RGV will no longer have to verify the residency of eligible patients who have registered to receive the COVID-19 vaccine from UT Health RGV. 

UT Health RGV already has administered more than 20,000 doses of the vaccine since December, and the new guidelines will make it easier for UT Health RGV to vaccinate more members of the Valley community. 

- Advertisement -

Anyone who already has registered with UT Health RGV to receive the vaccine but has been turned away because of their current residency should email covidvaccine@utrgv.edu to be rescheduled for the shots. 

NOTE: UT Health RGV’s vaccination registration remains temporarily closed to new registrants, until it can serve the more than 55,000 individuals who initially registered.  

UT Health RGV will reopen registration once the current registrants have been served and once the supply of vaccines provided by the State of Texas meets the current demand. 

For more information, visit the UT Health RGV vaccination webpage.  

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and Prevention (CDC), making it one of the nation's leading causes of death.
- Advertisement -